Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. | Semantic Scholar
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries | Journal of Hematology & Oncology | Full Text
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
![Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553933/bin/978-3-030-02278-5_72_Fig1_HTML.jpg "Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf")
Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink
New Prediction Model for 5-year Event-free Survival Rate from Ventricular Arrhythmia | Radcliffe Cardiology
Cureus | Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) - ScienceDirect
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer | PLOS ONE
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI | Haematologica
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM
Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and IPI.
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text
A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... | Download Scientific Diagram
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data - The Lancet Oncology
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance) | Blood Cancer Journal
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM
